Location & dates EMBL Heidelberg, Germany 8 - 10 Dec 2019
Deadlines Registration closed Abstract submission closed
organiser_WGC

Programme

Got something to say? Tweet it! #EWGtarget

Day 1 - Sunday 8 December 2019
TimeSpeaker
14:00 - 15:00 Arrival and Registration
with light refreshments
15:00 - 15:15 Opening remarks
15:15 - 16:00

Keynote speaker
FinnGen: a public-private partnership to mine genomics and health data for new paths to therapy

Mark Daly - Institute for Molecular Medicine Finland FIMM, Finland

16:00 - 19:00 Session 1 - Genetics
Chair:
Jeff Barrett - Genomics plc, UK
16:00 - 16:30

Translating immune disease GWAS variants to causal cell types and genes
Gosia Trynka - Wellcome Sanger Institute, UK

16:30 - 16:45 Human loss-of-function variants in >4 million individuals suggest that partial LRRK2 inhibition is a safe therapeutic strategy for Parkinson’s disease
Nicola Whiffin - Imperial College London, UK
16:45 - 17:00 Inhibition of angiotensinogen as a therapeutic strategy for lowering blood pressure: a Mendelian randomization study
Jonas Bovijn - University of Oxford, UK
17:00 -17:30 Big data meets drug discovery
Astrid Ruefli-Brasse - 23andMe, USA
17:30 - 18:00

Coffee Break and Meet the Speakers

18:00 - 18:30

Guiding targets to success: Experiences progressing genetically validated targets through discovery and development
Janna Hutz - Eisai Center for Genetics Guided Dementia Discovery, USA

18:30 - 18:45 Evaluating genetic support for lipid-modifying drug targets
Maria - Gordillo-Maranon, University College London, UK
18:45 - 19:00

A phenome-wide gene-based collapsing analysis of rare loss-of-function and missense variation in 136,508 UK Biobank exomes
Slavé Petrovski - AstraZeneca, UK

19:00 - 20:00

Dinner

20:00 - 22:00

Poster Session 1 (odd numbers)

Day 2 - Monday 9 December 2019
TimeSpeaker
09:00 - 12:00 Session 2 - Case studies
Chair:
Sandra Engle - Biogen, USA
09:00 - 09:30 Functional genetics and genomics cross-comparisons between immune-mediated diseases
Calliope Dendrou - Wellcome Trust Centre for Human Genetics, UK
09:30 - 10:00 From SNPs to biology in autoimmune disease                      
James Lee - University of Cambridge, UK
10:00 - 10:15 A cross-disciplinary, integrative approach to target prioritization
Katrina de Lange - Novartis, Switzerland
10:15 - 10:30

Identification of a candidate for breast cancer risk prevention
Jonathan Beesley- QIMR BERGHOFER, Australia

10:30 - 11:00

Coffee Break and Meet the Speakers

11:00 - 11:30 Genomics and Target Validation in Alzheimer's disease
Damien Crowther - AstraZeneca, UK
11:30 - 11:45 Investigating the causal relationship between glaucoma and Alzheimer’s disease: a mendelian randomization study
Ashley Budu-Aggrey- University of Bristol, UK
11:45 - 12:00 Investigating calcium channel isoforms to identify novel, genomically-informed treatment targets for psychiatric disorders
Nicola Hall - University of Oxford, UK
12:00 - 13:30

Lunch

13:30 - 16:30 Session 3 - Genome editing for target validation
Chair:
Gitte Neubauer - Cellzome, Germany
13:30 - 14:00 Advanced CRISPR applications in primary human T cells
Eric Shifrut - University of California, San Francisco, USA
14:00 - 14:15 Unbiased compound-target interface mapping by forward genetics
Moritz Horn - Acus Laboratories GmbH, Germany
14:15 - 14:30 Target discovery through functionall genomics
Samantha Peel - Astrazeneca, UK
14:30 -15:00

Modeling disease biology with human stem cell-derived cells and genomic editing to enable drug discovery
Sandra Engle - Biogen, USA

15:00 -15:30

Coffee Break and Meet the Speakers

15:30 -16:00 Mapping gene regulation with large-scale cellular genetic screens
Silvia Domcke - University of Washington, USA
16:00 - 16:15 CRISPR/Cas9 functional screens for long non-coding RNAs in lung cancer
Taisia Polidori - University of Bern, Switzerland
16:15 -16:30 Functional insights and enhanced target identification through co-essentiality
Martino Colombo - Celgene Research, Spain
16:30 - 18:30 Poster Session 2 (even numbers)
18:45 Buses depart to Christmas market and hotels
Day 3 - Tuesday 10 December 2019
TimeSpeaker
09:00 - 11:45 Session 4 - Relevant models for target validation
Chair:
Gosia Trynka - Wellcome Sanger Institute, UK
09:00 - 09:30 Understanding mechanisms of resistance: novel targets for cancer treatment
Dirk Jäger - National Center for Tumor Diseases, Germany
09:30 - 09:45 Functional genomic follow-up of GWAS to identify novel drug targets for endometrial cancer
Dylan Glubb - QIMR Berghofer Medical Research Institute, Australia
09:45 - 10:00 Functional genomic analysis uncovers mitophagy regulators associated with Parkinson’s disease risk
Daniela Melandri - University College London, UK
10:00 - 10:30

Organoid biobanks combine genetic and functional patient and disease data
Robert Vries - Hubrecht Organoid Technology, The Netherlands

10:30 - 11:00 Coffee Break and Meet the Speakers
11:00 - 11:15 Systematic prioritisation of genes at all GWAS trait-associated loci
Edward Mountjoy - Wellcome Sanger Institute, UK
11:15 - 11:45 Learning the manifold of human disease with the aim to establish a new approach to drug discovery
Paolo Casale - insitro, USA
11:45 - 13:15

Lunch

13:15- 16:15 Session 5 - Computational methods and analysis
Chair: 
Oliver Stegle - EMBL Heidelberg, Germany
13:15 - 13:45 Using genomics to evaluate T-cell therapeutic targets
Hans Bitter - bluebird bio, USA
13:45 - 14:00 Genetic drug target validation using Mendelian randomization
Amand Schmidt - University College London, UK
14:00 - 14:15 Network and pathway analysis of GWAS for target identification
Alex Gutteridge - GSK, UK
14:15 - 14:45 Therapeutic target identification through the inference of pathogenic cells and tissues
Jeff Barrett - Genomics plc, UK
14:45 - 15:15 Coffee Break and Meet the Speakers
15:15 - 15:30 Genome-wide investigation of gene-cancer associations for the prediction of novel therapeutic targets
Hendrik Weisser - STORM Therapeutics, UK
15:30 - 15:45 Reconciling GWAS and Mendelian genetics through core-gene identification
Patrick Deelen - University Medical Center Groningen, The Netherlands
15:45 - 16:30 Keynote speaker
Relevant phenotypic screens in complex systems

Edith Hessel - GSK, UK
16:30 - 16:45 Closing remarks and poster prize
17:00 Buses depart to downtown and airport